Lymphoma News

Patients with blood cancer appeared at greater risk for severe and life-threatening COVID-19 illness than healthy individuals and did not always achieve optimal protection from vaccination, according to a registry-based study in Blood.

In this video, Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center discusses three randomized trials testing CD19-directed autologous chimeric antigen receptor T-cell therapies against chemotherapy and autologous transplant in the second line setting for lymphoma, which were presented at ASH.

In this video, Rayne Rouce, MD, discusses the top chimeric antigen receptor T-cell therapy-related presentations at ASH.

Early clinical trials for the first chimeric antigen receptor T-cell therapies mandated recipients receive rigorous post-treatment monitoring, often requiring inpatient admittance lasting anywhere from 2 to 4 weeks.

Healio provided comprehensive coverage of this year’s ASH Annual Meeting and Exposition.

In this video, Joshua Sasine, MD, PhD, assistant professor of medicine hematology & cellular therapy at the Samuel Oschin Cancer Center Regenerative Medicine Institute, discusses a presentation from his group at ASH on the association between CAR T-cells and the cytopenia that commonly occur after therapy.

The FDA granted regenerative medicine advanced therapy designation to FT516, a natural killer cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Second-line tisagenlecleucel conferred identical EFS as standard treatment for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, according to randomized phase 3 results presented at ASH Annual Meeting and Exposition.

The addition of polatuzumab vedotin to chemotherapy significantly extended PFS compared with standard first-line treatment for patients with diffuse large B-cell lymphoma, according to results presented at ASH Annual Meeting and Exposition.

The combination of pembrolizumab and vorinostat demonstrated efficacy among patients with relapsed or refractory Hodgkin lymphoma, according to phase 2 study results presented at ASH Annual Meeting and Exposition.